August 2026 Research Update

Across two retrospective cohort studies, cancer linked to dermatomyositis and related muscle inflammation conditions clustered near the time symptoms began and was more common in people who were older at onset and had anti-TIF1gamma antibodies. [1] [2] A separate dermatomyositis age-comparison study also reported that cancer-related dermatomyositis occurred only in adult-onset disease, not juvenile-onset, and that older age at diagnosis tracked with higher cancer risk and higher death risk. [3]

In a Japanese multicentre cohort of 364 people with idiopathic inflammatory myopathies, 42 had cancer-associated myositis, and the risk was highest in the first year after muscle disease onset. [1] The same study created a five-factor risk model using anti-TIF1gamma, inflammation blood test levels (C-reactive protein), dermatomyositis subtype, age at onset, and family history of cancer, with good overall accuracy (AUC 0.86). [1]

In a single-center Greek cohort of 113 people, 25 had cancer-associated myositis, and anti-TIF1gamma and dermatomyositis subtype were linked with higher cancer risk, while anti-Jo1 was linked with lower risk. [2] In that study, most cancers were not causing symptoms and were detected through screening, and people with cancer-associated myositis had shorter survival than those without cancer. [2]

Both cohort and case-based reports suggested that cancer stage matters: in the Japanese cohort, survival was better with earlier-stage cancer than with advanced-stage cancer. [1] Two single-patient case reports described dermatomyositis-like skin problems improving after chemotherapy for breast cancer or small cell lung cancer, supporting the idea that, in some people, the skin or muscle symptoms can be driven by an underlying cancer. [4] [5]

For patients and caregivers, this set of studies adds detail to who, in these cohorts, was more likely to have cancer occur around the start of dermatomyositis: older age at onset and certain blood markers (especially anti-TIF1gamma) repeatedly showed up, and cancers were sometimes found before causing symptoms. [1] [2] The proposed risk model may help researchers and clinicians think about tailoring how cancer risk is discussed and evaluated, but it has not been validated outside the original setting, and these studies do not prove what screening approach is best for every person. [1]

One retrospective U.S. Veterans case series looked at what happened when people with a known history of inflammatory muscle disease (including dermatomyositis) later received immune checkpoint inhibitors for cancer. [6] In this small group, flares of the muscle disease were uncommon, but the evidence is limited because only eight confirmed cases were identified. [6]

Among 29,539 Veterans who received at least one immune checkpoint inhibitor, eight had confirmed pre-existing idiopathic inflammatory myopathy before cancer immunotherapy, including three with dermatomyositis. [6] One person had a flare after two doses that was treated with glucocorticoids and intravenous immunoglobulin, and one person developed immune-related colitis; no other immune-related side effects were reported in this series. [6]

The same paper reviewed four previously published cases of people with pre-existing inflammatory muscle disease who received checkpoint inhibitors, and three of those cases reported a flare. [6] This contrast highlights that flare risk is still uncertain and may vary depending on the patient group and how flares are captured in medical records. [6]

This evidence mainly matters for people who have dermatomyositis (or a related inflammatory muscle disease) and also have cancer where immune checkpoint inhibitors are being considered. [6] The available data are early and based on small numbers, so they cannot give a precise estimate of flare risk, and they do not identify which individuals are most likely to flare. [6]

Across these studies, researchers focused on whether specific antibodies and blood-based immune or inflammation markers can help identify people with dermatomyositis (DM) or related conditions who are more likely to have interstitial lung disease (ILD), including rapidly progressive ILD, or worse outcomes. Overall, anti-MDA5-positive DM repeatedly stood out as a situation where lung involvement was common and severe, and where additional markers seemed to further separate higher-risk from lower-risk groups. At the same time, several tools were based on retrospective data or conceptual models, so it remains uncertain how well they will perform across different hospitals and patient populations. [7] [8] [9] [10] [11] [12]

In a large single-hospital cohort of idiopathic inflammatory myopathies, anti-Ro52 antibodies were common and were especially frequent in anti-MDA5-positive DM and in antisynthetase syndrome. In anti-MDA5-positive DM, having anti-Ro52 (particularly together with anti-SSA) was linked to ILD, rapidly progressive ILD, and worse prognosis, while in antisynthetase syndrome anti-Ro52 mainly tracked with pulmonary involvement rather than prognosis. In other antibody-defined groups, anti-Ro52 added less clinical information. [7]

In an Australian multicenter cohort where anti-MDA5 antibodies were detected by a line immunoblot blood test, only a minority of test-positive patients matched a clinical diagnosis of anti-MDA5 dermatomyositis, and stronger test signal intensity aligned with better clinical concordance. All clinically concordant patients had ILD, and deaths were concentrated among those with rapidly progressive ILD; pneumomediastinum (air leakage into the chest area) occurred in about one-third of concordant patients and was seen in several of the fatal cases. Higher ferritin and a higher neutrophil-to-lymphocyte ratio were reported in the rapidly progressive ILD subgroup. [8]

Two exploratory studies in dermatomyositis highlighted additional blood markers that might refine risk estimates in anti-MDA5-positive disease. One retrospective dermatomyositis cohort reported higher serum amyloid A (SAA) levels in DM than in healthy controls and especially high levels in rapidly progressive ILD, with the combination of SAA plus anti-MDA5 showing the highest diagnostic accuracy for rapidly progressive ILD in that dataset. Another small retrospective cohort of anti-MDA5 DM found that lower baseline CD4 memory T-cell counts (a specific immune cell subset measured by flow cytometry) were linked to higher 180-day mortality, but the authors noted the need for independent validation. [9] [10]

For antisynthetase syndrome-associated ILD, a retrospective study used computer-based clustering to sort 134 adults into three phenotypes with different lung progression and survival patterns, including a more fibrotic cluster with higher rates of progressive fibrosing disease and the highest mortality. The same study reported a simple decision-tree approach using CYFRA21-1, albumin, and neutrophil count to assign patients to these clusters with moderate accuracy in internal validation, but it lacked external validation. Separately, an exploratory framework paper in juvenile dermatomyositis described an interferon-driven biology-based way of thinking about lung vulnerability, noting that autoantibody testing is currently the most clinically actionable piece while cytokine and interferon-related markers remain investigational. [11] [12]

For patients and caregivers, this body of research mainly adds context about why clinicians often pay close attention to antibody results (such as anti-MDA5 and anti-Ro52) when discussing lung involvement in dermatomyositis and related conditions. Several additional blood tests (for example, serum amyloid A, specific T-cell subsets, and fibrosis-related markers) are being studied as ways to sort people into different lung-risk groups, but most evidence here is retrospective or exploratory and may not apply the same way in every clinic. The biggest uncertainty is which of these newer markers will prove reliable across different populations and become part of routine lung monitoring in the future. [7] [8] [9] [10] [11] [12]

This registry study suggests that people with antisynthetase syndrome who have dermatomyositis-type skin findings keep the typical antisynthetase features, especially interstitial lung disease (ILD), which sets them apart from people with dermatomyositis. It also highlights that among people who have dermatomyositis-like rashes, certain accompanying features can help separate antisynthetase syndrome from dermatomyositis at the clinical-pattern level (without implying any single sign is definitive). The evidence comes from a cross-sectional registry snapshot, so it describes co-existing features rather than showing what causes what or what will happen next. [13]

In the Myo-Spain registry, antisynthetase syndrome patients with dermatomyositis-type skin involvement were more likely to have periungual capillary changes (nailfold blood vessel changes) than antisynthetase patients without these skin findings. When comparing people who had dermatomyositis-type skin lesions, an antisynthetase syndrome diagnosis was strongly linked with ILD and was also linked with Raynaud's phenomenon and mechanic's hands, while classic dermatomyositis features like heliotrope rash or Gottron signs/papules and muscle weakness at diagnosis were less common. Malignancy was reported less often in antisynthetase syndrome with dermatomyositis-type skin than in dermatomyositis. [13]

This research is most relevant for people who have dermatomyositis-like skin changes and are being evaluated for whether their overall illness pattern fits dermatomyositis or antisynthetase syndrome, since the two can overlap in appearance. The key takeaway is that, in this registry, dermatomyositis-type skin involvement in antisynthetase syndrome tended to travel with ILD and certain hand and circulation-related features, which may influence how clinicians think about lung risk in that subgroup. What remains uncertain is how well these patterns predict future lung outcomes over time, because the study looked at patient features at a single point rather than tracking progression. [13]

Across this month's papers, multiple treatments aimed at specific immune pathways were linked to better dermatomyositis symptoms, especially skin disease, with some evidence for muscle and lung improvement as well. The strongest evidence came from a large placebo-controlled trial focused on skin outcomes, while smaller studies and case reports explored treatments for harder-to-treat situations such as anti-MDA5 disease with rapidly worsening lung involvement. Safety signals were treatment-specific, with infections highlighted most clearly in studies that included JAK-inhibitor based approaches. [14] [15] [16] [17] [18] [19]

In a phase 3 randomized trial analysis, brepocitinib 30 mg improved skin activity compared with placebo starting by week 4, and it also improved itch and skin-related quality of life; higher rates of near-clear skin and remission-level skin improvement were reported through week 52. The report stated that safety looked similar to other medicines in the same general drug class (JAK and TYK2 inhibitors). [14]

In a phase II study with an open-label extension, dazukibart (an antibody targeting interferon-beta signaling) was linked to continued improvement in skin scores and overall improvement measures through week 76, and benefits persisted during a 16-week follow-up after stopping treatment. In the extension group, side effects were mostly mild or moderate, and there were no treatment-related serious side effects or treatment stops due to side effects. [18]

In a 40-person retrospective cohort, upadacitinib treatment over 6 months was linked to improvements in an overall disease activity score, skin involvement, muscle strength testing, and interstitial lung disease measures, along with lower glucocorticoid use. Infections were common (17 people), including cytomegalovirus in the blood and shingles, and 4 people who were anti-MDA5 positive worsened or relapsed. [15]

For anti-MDA5 dermatomyositis with rapidly progressive interstitial lung disease, a 3-person case series described improvement in symptoms, scans, and lung function after an intensive combination that included high-dose glucocorticoids, rituximab, and upadacitinib (with intravenous immunoglobulin in some cases). One person developed serious opportunistic infections (tuberculosis and Pneumocystis pneumonia), underscoring that infection risk may be substantial with intensive immune suppression. [16]

A separate single-patient report described a 60-year-old woman with anti-MDA5 clinically amyopathic dermatomyositis and rapidly progressive interstitial lung disease who improved after four sessions of therapeutic plasma exchange when steroids, tacrolimus, and intravenous immunoglobulin had not worked. Because this is one person s experience, it cannot show how often this approach helps or how safe it is across patients. [17]

In a 5-person retrospective case series of difficult-to-treat inflammatory muscle disease, obinutuzumab was used after rituximab was not tolerated or did not work well; 4 of 5 people had substantial or complete improvement by later follow-up, and lung disease was stable or improved in all who had it. The authors reported no major safety concerns in this small group, but the sample was very limited. [19]

For patients and caregivers, these studies add context that dermatomyositis research is testing several ways to calm overactive immune signaling, with the clearest trial evidence this month focused on improving skin symptoms (including itch) over about a year. Smaller real-world studies and case reports suggest some approaches may also help lung involvement in certain situations, but they also highlight that infection risk can be an important tradeoff, especially with stronger or combined immune-suppressing regimens. It remains uncertain which patients are most likely to benefit from each option, particularly for anti-MDA5 disease where responses were mixed across reports. [14] [15] [16] [17] [18] [19]

This month included studies looking less at a single medicine s average effect and more at why some people do better or worse over time. In retrospective cohorts, antibody status and detailed immune-cell measurements were linked to relapse risk or response after rituximab, suggesting that immune profiling may help explain different paths people experience. Separately, laboratory research tested a new way of blocking an immune alarm system (STING) and showed reduced inflammatory signals in dermatomyositis blood cells and in an animal model. [20] [21] [22]

In a 132-person retrospective cohort of idiopathic inflammatory myopathies, about two-thirds reached complete remission after initial treatment, but relapses still occurred (43 people). Anti-ARS antibody positivity was linked to higher relapse risk, and among people treated again for relapse, a moderate-dose glucocorticoid approach combined with two immunosuppressants or biologics was reported to have the lowest rate of a second relapse, without more severe side effects in this dataset. [20]

In a 44-person retrospective cohort of idiopathic inflammatory myopathies treated with rituximab, early and deeper depletion of certain B-cell subsets (memory B cells and plasmablasts) at 2 weeks was linked to a better clinical response at 4 to 6 months. Standard B-cell count thresholds did not predict response, suggesting that more sensitive immune-cell testing may capture differences that routine tests miss. [21]

In lab and mouse-model research, benzofuran compounds designed to disrupt STING signaling reduced inflammatory gene activity in patient-derived blood immune cells, including cells from 10 people with dermatomyositis, and reduced inflammation in a myositis model. This work is preclinical, meaning it does not yet show whether these compounds are safe or effective as treatments in people with dermatomyositis. [22]

For patients, this theme is mainly about understanding variability: why some people relapse and why responses to immune therapies differ. The relapse and rituximab studies are based on looking back at real-world care, so they can point to patterns (like antibody status or immune-cell depletion) but cannot prove cause and effect. The STING study is background research that could inform future drug development, but it is not evidence of a new available treatment yet, and many questions remain about long-term safety and which dermatomyositis subtypes would benefit most. [20] [21] [22]

Across these papers, the main message is that calcinosis (calcium deposits in the skin or muscle) can improve, but the evidence is still limited. One small study in children measured a decrease in overall calcinosis burden on imaging after adding a targeted immune treatment, while two case reports show that outcomes can vary and may involve long-term, multi-part care including surgery in selected situations. Because most data here are from exploratory research and individual cases, it is still unclear how well these results apply to different people or how long benefits last. [23] [24] [25]

In an open-label study of 20 children and teens with juvenile dermatomyositis and calcinosis, adding tofacitinib to standard therapy was linked to a reduction in calcinosis burden on low-dose whole-body CT scans (Agatston score) at follow-up after about six months. Type I interferon blood levels went down over the same period, and there were no serious safety issues reported, although 4 of 20 participants did not show a reduction in calcinosis score. Because there was no comparison group and follow-up was short, it remains uncertain how much of the change was due to tofacitinib versus other factors, and whether improvements continue long term. [23]

One case report described an 11-year-old boy where calcinosis cutis was a leading early sign of juvenile dermatomyositis; he improved after initial prednisone (with falling muscle enzymes), then intravenous immune globulin along with longer-term immune-suppressing medicines, with remission and normalized muscle strength reported at 6 months. His care plan also included a medicine sometimes used for calcinosis and surgical removal of lesions, with ongoing follow-up reporting no flare-ups. As a single-patient report, it cannot show which part of treatment mattered most, or whether similar results would occur in others. [24]

A second case report focused on an adult who had juvenile dermatomyositis in long-term remission but later developed infected calcinosis in the calf muscle (gastrocnemius), with infection complications during the course. After conservative management did not work, surgeons removed the calcified medial gastrocnemius and part of the Achilles tendon area, and the patient had full functional recovery with no recurrence reported at 1 year. This illustrates that, in select severe or infected cases, extensive surgery may be considered and can be followed by good function, but it is still only evidence from one person. [25]

For patients and caregivers, this set of studies suggests that calcinosis in juvenile dermatomyositis may decrease over months in some children when additional immune-targeting treatment is added, but responses are not uniform and longer follow-up is missing. The case reports provide real-world examples of how calcinosis can be part of early disease in a child, or can reappear later in adulthood and even become infected, sometimes leading to surgical treatment. Overall, these papers add background on possible approaches and outcomes, while leaving key uncertainties about who benefits most, durability of change, and how results compare with other care strategies.

Across this month's papers, a consistent message was that dermatomyositis and related muscle-inflammation conditions are not one single disease, and using more than one type of test can change or clarify the subtype. Antibody patterns, muscle biopsy details, and muscle imaging each added different information about which organs were most involved (muscle, skin, or lungs). Newer blood protein profiling aimed to capture these differences in a single blood draw, but this approach is still early-stage research. [26] [27] [28]

In a 36-person adult cohort of idiopathic inflammatory myopathies in Cyprus, adding myositis-related antibody testing and muscle biopsy review changed how some people were classified compared with older labels, especially for cases previously called polymyositis. In the dermatomyositis subgroup, the most common antibody reported was anti-TIF1 gamma (4 of 7), and one patient had lung involvement; the authors emphasized that pairing antibody results with biopsy patterns can improve subtype confidence. [26]

A single-center imaging study compared thigh MRI patterns across dermatomyositis antibody subtypes and reported that anti-Mi2-positive dermatomyositis had the most severe thigh muscle swelling on MRI, often worst in the quadriceps. Higher MRI swelling scores tracked with higher muscle enzyme levels in blood and lower strength scores, and in a very small follow-up group (6 people) the MRI swelling decreased with remission and returned with relapse. This suggests MRI can reflect muscle activity over time, but the study was exploratory and not designed to be a stand-alone diagnostic test. [27]

In a 201-person cohort using large-scale blood protein profiling, dermatomyositis showed enrichment of interferon-related and skin-related proteins compared with other myositis types, while lung-related proteins were more prominent in anti-synthetase syndrome and muscle-related proteins in immune-mediated necrotizing myopathy. The study also reported that a muscle-related protein score correlated with common measures of muscle disease activity, and that people with certain antibodies linked to lung disease showed different patterns of surfactant proteins and interferon pathway signals. These results support the idea that blood proteins may one day help describe organ involvement, but the authors noted important limits and potential biases in interpreting tissue-of-origin signals from blood. [28]

One case report highlighted how dermatomyositis can be mistaken for other causes of weakness at first. A young man initially labeled as having hypothyroid-related muscle disease continued to have symptoms despite thyroid levels normalizing, and later muscle biopsy plus broad antibody testing identified anti-Ku-positive dermatomyositis with characteristic biopsy features (including perifascicular atrophy). As a single patient, this mainly illustrates how extended antibody testing and biopsy can clarify an unclear diagnosis. [29]

For patients and caregivers, these studies reinforce that dermatomyositis is often approached using a combination of information rather than any single test: blood antibody panels, muscle biopsy findings, and sometimes MRI patterns can each add pieces about subtype and which organs may be most involved. The large blood-protein study is best viewed as background research for future biomarker development, because it does not yet establish a standard test for routine care. Important uncertainties remain, including how well these newer protein signatures perform across hospitals and populations, and how they should be interpreted alongside established antibody tests and clinical evaluation. [26] [27] [28] [29]

Across this group of papers, the overall picture is that dermatomyositis can sometimes affect organs beyond muscles and skin in ways that are easy to miss at first, especially the voice box and lungs, and more rarely the blood vessels or bleeding system. Most of the detailed reports are single-patient case reports, so they show what can happen but cannot tell how common these problems are. A separate large review in juvenile dermatomyositis highlighted that long-term complications such as calcium deposits under the skin can remain important into adulthood. [30] [31] [32] [33]

Voice changes were common in a very small cross-sectional study of women with autoimmune muscle diseases, where dermatomyositis was the most frequent diagnosis; all participants had mild changes on clinician-rated voice quality, and most reported noticeable voice complaints on questionnaires. Several objective sound measures also looked abnormal, supporting that symptoms can have measurable voice changes even when they are mild. [34]

A separate case report in a 21-year-old man showed dermatomyositis involving the voice box, with hoarseness, breathy voice, and episodes of swallowing difficulty and aspiration; camera-based throat exams showed incomplete vocal cord closure and reduced vibration. After starting mycophenolate mofetil, his voice symptom score improved within one month, although repeat imaging was not available to confirm physical changes. [30]

Several reports focused on rare, serious complications in specific antibody-defined types of dermatomyositis. One man in his 30s with anti-NXP2 dermatomyositis developed massive body swelling, severe swallowing and bulbar problems requiring a feeding tube, and respiratory failure; he improved over time but had major complications including a pulmonary embolism, pneumonia, and gastrointestinal bleeding. [35]

Another anti-NXP2 case described a 61-year-old man who developed a spontaneous retroperitoneal hematoma (internal bleeding behind the abdomen) soon after starting corticosteroids and recovered after hospital-based supportive and immune-focused care; the authors noted that any link between anti-NXP2 antibodies and bleeding risk remains uncertain. [32]

In anti-MDA5 dermatomyositis, one case described pulmonary arterial hypertension alongside difficult-to-heal skin ulcers, with improvement after a combination rescue regimen that included rituximab and mycophenolate mofetil (with bosentan also used), followed later by maintenance therapy; the report also included a successful pregnancy after remission. Another anti-MDA5 case described secondary pulmonary alveolar proteinosis, which can resemble worsening interstitial lung disease on evaluation, highlighting that not all apparent lung progression is the same process. [36] [31]

Two additional case reports described a rare skin lymphoma (primary cutaneous gamma-delta T-cell lymphoma) arising in women with long-standing dermatomyositis receiving long-term immunosuppression; one case went into complete remission after intensive cancer therapy, while the other had a slower course with partial spontaneous regression. These reports suggest that unusual new painful skin nodules in heavily immunosuppressed dermatomyositis can sometimes represent conditions other than inflammatory skin disease, but they do not establish how often this occurs. [37]

Looking at broader, longer-term patterns in childhood-onset disease, a large systematic review and meta-analysis pooling 2,729 juvenile dermatomyositis patients estimated calcinosis (calcium deposits) at about 29.7% in childhood and about 40.4% in adulthood, with other reported issues including growth failure, contractures, and later lipodystrophy. The authors emphasized that results varied widely across studies, which limits precision. [33]

For patients and caregivers, these papers mainly serve as background on the range of less-common dermatomyositis complications that may involve the voice box (hoarseness, voice fatigue, swallowing/aspiration), lungs (including pulmonary arterial hypertension or other conditions that can mimic lung inflammation), and rarely severe swelling or internal bleeding. Because most evidence here comes from single-patient reports, it is still uncertain how often these problems occur, who is most at risk, and how reliably antibody type predicts them; the juvenile dermatomyositis meta-analysis is larger but had high study-to-study variability. Overall, the practical value right now is awareness that symptoms outside muscles and skin have been documented in dermatomyositis and may need careful medical evaluation to sort out the cause.

Across the larger-dataset studies in this group, the common thread is that people with dermatomyositis may be captured in broader patterns of comorbidity and risk that are best studied with population data, but these studies cannot prove cause and effect. One study compared mortality and demographics between dermatomyositis and polymyositis, while another tested whether irritable bowel syndrome (IBS) is linked to later systemic rheumatic disease diagnoses, including dermatomyositis/polymyositis. A separate pediatric case series on Listeria meningitis provides context on severe infections and immune backgrounds, although it was not specific to dermatomyositis. [38] [39] [40]

In an Oklahoma electronic health record cohort (321 adults), dermatomyositis was more common in women, and polymyositis was more prevalent among African American individuals. Increasing age at diagnosis was linked to mortality, and the study did not find a statistically significant mortality difference between dermatomyositis and polymyositis. Limits included reliance on diagnostic codes and missing details such as treatment history or cancer status. [38]

In a very large TriNetX electronic health record study (about 460,000 adults with IBS and the same number of matched controls), IBS was linked to a higher risk of several later systemic rheumatic disease diagnoses. For dermatomyositis/polymyositis specifically, the reported hazard ratio was 1.52, meaning the IBS group had more new diagnoses over time than controls in this dataset. The authors noted possible confounding, misclassification from codes, and surveillance bias (people with IBS may have more medical visits). [39]

A multicenter pediatric case series described 11 cases of Listeria monocytogenes meningitis beyond the newborn period, with mortality and severe long-term complications each reported at 18.2%. Cerebrospinal fluid (CSF) testing was often positive by culture and was positive by PCR in all tested patients, and four children had immune-related conditions. One case had brain imaging that mimicked autoimmune limbic encephalitis, showing how infection can sometimes resemble autoimmune disease on scans. [40]

These studies help describe who is affected and how different diagnoses may cluster in real-world data, but they do not explain why those links exist. The IBS study suggests a statistical link between IBS and later connective tissue disease diagnoses (including dermatomyositis/polymyositis) that may matter most for researchers studying shared immune pathways; it does not show that IBS causes dermatomyositis. The infection case series is relevant mainly as background that serious infections can occur in children, sometimes in the setting of immune problems, and can look similar to autoimmune disease on testing; it is not evidence about typical dermatomyositis complications.